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Aspirin suppresses chemoresistance 
and enhances antitumor activity 
of 5-Fu in 5-Fu-resistant colorectal 
cancer by abolishing 5-Fu-induced 
NF-κB activation
Jinbo fu2,5, Yiming Xu2,5, Yushan Yang1,3,4,5, Yun Liu2, Lulu Ma1,3,4 & Yiyao Zhang1,3,4*
Chemoresistance to 5-fluorouracil (5-Fu)-based chemotherapy is a leading obstacle in achieving 
effective treatment for colorectal cancer (CRC). Typically, NF-κB activation induced by the 
chemotherapeutics themselves is an important cause resulting in chemoresistance. Specifically, 
NF-κB activation can inhibit tumor cell apoptosis and induce chemoresistance. Drugs that can prevent 
NF-κB activation induced by chemotherapeutics are urgently needed to overcome chemoresistance. 
Obviously, aspirin is one of these agents, which has been demonstrated to possess antitumor activities 
and as an inhibitor of NF-κB. The current study aimed to investigate whether aspirin was able to 
overcome the chemoresistance to 5-Fu in CRC, together with the potential synergistic mechanisms. 
Our results suggested that aspirin remarkably potentiated the inhibitory effect of 5-Fu on the growth 
and invasion of resistant cells in vitro. In vivo, aspirin markedly enhanced the antitumor activity of 5-Fu 
in suppressing tumor growth and metastasis, and down-regulating the expression of NF-κB-regulated 
genes in the 5-Fu-resistant cells. Obviously, aspirin completely eradicated the 5-Fu-induced NF-κB 
activation, without inducing pronounced adverse effects. Taken together, findings in this study suggest 
that aspirin can reverse chemoresistance and potentiate the antitumor effect of 5-Fu, which is achieved 
through abolishing the 5-Fu-induced NF-κB activation, suggesting that aspirin may be a promising 
adjuvant therapeutic agent for CRC.
Colorectal cancer (CRC), one of the most common malignancies, accounts for the second leading cause 
of cancer-related deaths in the USA1. An increasing number of new agents have emerged, nonetheless, the 
5-fluorouracil (5-Fu)-based combined chemotherapy remains the preferred choice for CRC patients. However, 
the overall response rate of CRC to 5-Fu is <15% due to the intrinsic or acquired chemoresistance in exposure to 
5-Fu2. The presence of chemoresistance has prompted 50% patients to develop liver metastasis during disease pro-
gression eventually3,4. Although treatment with 5-Fu in combination with other chemotherapeutics can improve 
the response rate, it will also remarkably lead to severe adverse effects (AEs)4. Therefore, it is urgently needed to 
develop the less toxic agents to enhance the sensitivity of CRC cells to 5-Fu or to prevent the resistance to 5-Fu.
Aspirin has been extensively used clinically as an agent to prevent cardiovascular events. Moreover, both 
epidemiological and clinical studies have demonstrated that aspirin can potentially reduce the incidence and 
metastasis of CRC5–8. One recent study demonstrates that aspirin probably improves the clinical outcomes of 
metastatic CRC patients receiving capecitabine, a derivative of 5-Fu, after the failure of standard chemotherapy9. 
Such results suggested that aspirin potentially boosted the chemosensitivity of CRC to 5-Fu-based chemotherapy. 
The mechanisms underlying the antitumor activity of aspirin remain hypothetical and complex, yet it may be one 
of the critical mechanisms that the antitumor effect of aspirin on CRC targets nuclear factor- κB (NF-κB), the 
transcription factor10,11.
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NF-κB has been reported in numerous studies to exert an important role in tumorigenesis, tumor chemore-
sistance and metastasis, which is achieved through mediating the transcription of a serial of genes, including 
pro-proliferative gene cyclin D1, anti-apoptotic gene Bcl-2 and Survivin, and the angiogenetic gene VEGF12–16. 
The ability to induce NF-κB translocation and activate its target genes is one common feature of chemother-
apeutics, which is the main reason that tumor can acquire chemoresistance to the anticancer agents10. Thus, 
inhibiting NF-κB activation can reverse the chemoresistance and enhance the efficacy of anticancer agents 
in numerous cancer types, including CRC10,17–20. Recently, NF-κB has been identified as a crucial regulator 
of epithelial-mesenchymal transition (EMT) in CRC21, which is essential for tumor metastasis and chemore-
sistance22,23. NF-κB over-expression is also closely associated with advanced CRC, which may predict a worse 
overall survival24. Consequently, the NF-κB pathway represents a potentially promising therapeutic target, and 
NF-κB inhibitors can be used to overcome the chemoresistance of CRC to chemotherapeutics. Although there are 
overwhelming proofs that aspirin can prevent CRC, very few studies have focused on the underlying mechanism 
of action by which aspirin improves the sensitivity of chemoresistant CRC to chemotherapeutics.
In this study, the innate or acquired resistance of 5-Fu in CRC cells was mimicked to assess whether aspirin 
reversed the resistance of CRC cells to 5-Fu and to further investigate the underlying synergic mechanisms. Our 
results suggested that aspirin, as a sensitizer, reversed the chemoresistance of CRC cells to 5-Fu and enhanced 
the antitumor effects of 5-Fu both in vivo and in vitro, without inducing additional toxicity, and such effects were 
achieved by abolishing the 5-Fu-induced NF-κB activation.
Materials and Methods
Established human CRC cell lines and reagents. The established human CRC cell lines SW480 and 
SW620 were obtained from American Type Culture Collection (ATCC) and cultured in the Dulbecco’s modi-
fied eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Then, cells were incubated in a 
humidified incubator under 37 °C and 5% CO2 conditions. Additionally, the 5-Fu resistant cell lines SW480-FU 
and SW620-FU were derived through gradually increasing 5-Fu concentrations in SW620 and SW480 cell lines, 
as described previously17. After sequential 5-Fu treatments from 10 μM to 100 μM for 3 months, both SW480-FU 
and SW620-FU cell lines were selected from the parental cell lines, which were totally resistant to 100μM 5-Fu. 
Moreover, mycoplasma tests were also performed monthly to ensure that the cultures were mycoplasma-negative. 
Aspirin and 5-Fu were purchased from the Pharmacy of Zhongshan Hospital of Xiamen University and Sigma, 
respectively. Notably, aspirin and 5-Fu powder were dissolved in dimethyl sulfoxide (DMSO) and preserved in 
aliquots at −20 °C. The final solvent concentrations in the medium were <0.1%.
Cell viability assay. Cell viability was determined according to the 3-(4,5-dimethylthiazol-2-yl)-2, 
5-diphenyltetrazolium bromide (MTT) assay, as described in a previous study17.
Detection of apoptosis. Alexa fluoresceinisothiocyanate-conjugated Annexin V (BD Bioscience, San Jose, 
CA, USA) was employed to determine the number of apoptotic cells in accordance with manufacturer protocols, 
as described previously17.
Western blotting. Western blotting was performed as previously described17. In brief, the whole-cell or 
nuclear extracts from CRC cells and tumor samples were prepared according to a standard protocol. Then, the 
samples were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) for sep-
aration. Afterwards, the separated samples were transferred onto the polyvinylidene difluoride (PVDF) mem-
branes (Millipore, CA). Later, the membranes were blocked with 5% milk and incubated with the following 
primary antibodies, including p65 and p-p65 (Santa Cruz Biotechnology, CA, USA), cyclin D1, VEGF, Bcl-2, 
Survivin, Ki67 (Abcam, Cambridge, UK), cleaved Caspase-3, p-IKK-β, and p-IKK−α (Cell Signaling, MA, USA) 
antibodies, at 4 °C overnight, followed by incubation with secondary antibodies. Finally, the proteins were visu-
alized using the ECL detection reagent.
Electrophoretic mobility shift assay (EMSA). EMSAs were carried out as described previously25. 
Briefly, the nuclear extracts from CRC cells and tumor samples were incubated with the radiolabeled DNA 
probes containing a consensus κB site for 30 min at room temperature. Later, the formed DNA-protein complexes 
were separated from the free oligonucleotides on the native 4% polyacrylamide gel and visualized by means of 
autoradiography.
Transfection of small interfering RNA. Cells in 6-well plates or 96-well plates were grown to 50% con-
fluence and transfected with p65 siRNA (Dharmacon Res Inc.) or with a siRNA nonspecific control (Ambion, 
Austin, TX cat# 4611). Cells were incubated for 48 h and p65 protein expression was then confirmed by Western 
blotting. Alternatively, cells were treated with 5-FU or aspirin or both agents together for another 72 h. Then, the 
viability of siRNA-transfected cells under different treatments were detected with MTT.
Migration and invasion assays. The migration and invasion capacities of cells were evaluated through 
Transwell assay. In brief, the Transwell chambers were coated with or without 100 mL diluted matrigel (Costar, 
Cambridge, MA). Then, cells were suspended within 100 µl serum-free medium and seeded into the upper 
Transwell chamber at a density of 2 × 105 cells/ml, whereas the lower Transwell chamber was filled with medium 
containing 10% FBS. After treatment for 48 h in each group, cells on the upper chamber surface that had not 
migrated were carefully removed with a cotton swab. Afterwards, the remaining cells were fixed with cold 95% 
ethanol, and stained with 0.1% crystal violet. The experiments were repeated in triplicate wells, and the number of 
migrating cells was quantified by counting the cells in five random fields per filter under the microscope.
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Xenografts in nude mice. All animal experiments and procedures were carried out in accordance with the 
protocol approved by the Animal Care and Ethics Committee of Xiamen University. To confirm the above results 
in animals, both SW620 and SW620-FU cell lines were selected to form the xenografts in nude mice. Briefly, 
SW620 (1 × 106) or SW620-FU (5 × 105) cells were suspended within 100 μL matrigel diluted in DMEM (1:1), 
which were then injected into the left rear flank of the 6-to-8-week-old female Balb/c nude mice (day 0). After 3 
days of implantation when tumors had reached a palpable size, mice bearing tumors from SW620 cells were ran-
domly divided into 4 groups (n = 7 in each group) and treated as follows: (a) control group (100 μL of 0.9% saline, 
oral gavage, daily); (b) aspirin group (200 mg/kg aspirin dissolved in saline, oral gavage, daily); (c) 5-Fu group 
(20 mg/kg, intraperitoneal injection, twice weekly); and (d) 5-Fu combined with aspirin group (20 mg/kg 5-Fu, 
intraperitoneal injection, twice weekly; and 200 mg/kg aspirin dissolved in saline, oral gavage, daily). Similarly, 
40 mice bearing tumors from SW620-FU cells were also randomly divided into 8 groups (n = 5 in each group) 
and treated as follows: (a) control group (100 ml of 0.9% saline, oral gavage, daily); (b) low-dose aspirin group 
(100 mg/kg aspirin dissolved in 0.9% saline, oral gavage, daily); (c) moderate-dose aspirin group (200 mg/kg 
aspirin dissolved in saline, oral gavage, daily); (d) high-dose aspirin group (300 mg/kg aspirin dissolved in 0.9% 
saline, oral gavage, daily); (e) 5-Fu group (25 mg/kg, intraperitoneal injection, twice weekly; 100 μl of 0.9% saline, 
oral gavage, daily); (f) 5-Fu combined with low-dose aspirin group (25 mg/kg 5-Fu, intraperitoneal injection, 
twice weekly; 100 mg/kg aspirin dissolved in saline, oral gavage, daily); (g) 5-Fu combined with moderate-dose 
aspirin group (5-Fu, 25 mg/kg, intraperitoneal injection, twice weekly; 200 mg/kg aspirin dissolved in saline, oral 
gavage, daily); and (h) 5-Fu combined with high-dose aspirin group (25 mg/k 5-Fu, intraperitoneal injection, 
twice weekly; 300 mg/kg aspirin dissolved in saline, oral gavage, daily). The animals were euthanized on day 23 
and the tumors were excised. The tumor volume was calculated for three times a week according to the following 
formula: V = 1/2 (length × width2). Moreover, the tumor tissues were immediately frozen in liquid nitrogen and 
preserved at −80 °C.
Splenic vein metastasis assay in mice. To evaluate liver and spleen metastases, SW620-FU cells (5 × 105) 
were injected into the 6-to-8-week-old Balb/c nude mice through the splenic vein. Typically, 28 mice were divided 
into 4 groups, with 7 in each group, and animals were anaesthetized after 5 weeks to assess the liver and spleen 
metastases.
Statistical analysis. The significance of data was analyzed using the Student’s t-test for parametric data and 
the Mann-Whitney test with Bonferroni corrections for non-parametric data. A difference of P < 0.05 was con-
sidered as statistically significant (*P < 0.05, **P < 0.01).
Results
Aspirin enhanced the cytotoxicity of 5-Fu in chemoresistant CRC cells. Both SW480 and SW620 
cells had innate resistance and derived from the same patient, among which, SW480 cells were obtained from 
the primary lesion, whereas SW620 cells were acquired from the metastases, but they showed distinctly different 
sensitivities to 5-Fu. For instance, the IC50 values of 5-Fu based on our MTT data were 18.8 μM for SW480 cells 
and 29.1 μM for SW620 cells at 72 h (Supplementary Fig. 1). To induce the acquired resistance to 5-Fu, both 
SW480 and SW620 cells were incubated with 5-Fu at increasing concentrations for several months, so as to 
obtain the 5-Fu resistant SW480-FU (IC 50: 216.9 μM at 72 h) and SW620-FU (IC 50: 231.4 μM at 72 h) cell lines 
(Fig. 1A). According to our MTT results, the cell viability was only partly inhibited when treated with 150 μM 
5-Fu in SW480-FU and SW620-FU cells, so 150 μM 5-Fu was selected as the concentration for use in subsequent 
experiments.
To examine whether there was cross-resistance between aspirin and 5-Fu, the effects of aspirin on the pro-
liferation of 5-Fu-resistant SW480-FU and SW620-FU cells, as well as the parental SW480 and SW620 cells, 
were detected by MTT assay. The results showed that aspirin reduced cell viability in a dose-dependent man-
ner, and no obvious difference was observed between 5-Fu-resistant cells and their parental cells, suggesting no 
cross-resistance between aspirin and 5-Fu (Fig. 1A–C).
To assess whether aspirin boosted the sensitivity of chemoresistant CRC cells to 5-Fu, the 5-Fu-resistant cells 
and parental cells were treated with aspirin, 5-Fu alone, or the combination of these two drugs, and cell viabil-
ity was assessed at 48 h and 72 h, respectively, by MTT assay. As expected, 5-Fu had the minimal effect on both 
5-Fu-resistant cells and the parental cells. However, the combined treatment had exerted the greatest effect on 
inhibiting the proliferation of all the four cell lines in a time-dependent manner, especially in SW480-FU and 
SW620-FU cells, revealing that the combined treatment effectively overcame the chemoresistance of CRC to 5-Fu 
(Fig. 1B,C)
Next, cell apoptosis was detected through flow cytometry. Compared with aspirin, aspirin combined with 
5-Fu had a more pronounced effect on inducing apoptosis relative to that of 5-Fu alone (Fig. 1D).
Taken together, these results demonstrated that aspirin enhanced the sensitivity of CRC cells to 5-Fu and 
increased the cytotoxicity of 5-Fu in chemoresistant CRC cells.
Aspirin inhibited restored the sensitivity of chemoresistant CRC cells to 5-Fu by abolishing 
5-Fu-induced NF-κB activation in vitro. To further examine the underlying molecular mechanism for 
the chemoresistance to 5-Fu, the activation of the NF-κB signaling in 5-Fu,resistant SW480-FU and SW620-FU 
cells and their parental cells SW480 and SW620 was investigated. Our results suggested that the expression of p65, 
a key subunit of NF-κB, was dramatically up-regulated in 5-Fu resistant cells compared with that in their parental 
cells (Fig. 2A). To further verify the above results, the activity of NF-κB was tested by EMSA, and the results also 
indicated that the 5-Fu resistant cells showed higher basic NF-κB activity than that in their parental cells (Fig. 2B).
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Subsequently, Western blotting and EMSA were carried out to investigate whether aspirin sensitized the 
chemoresistant CRC cells through affecting the NF-κB pathway. Unexpectedly, our results demonstrated that the 
5-Fu-induced the expression of NF-κB (p65, p-p65), and that aspirin treatment not only evidently reduced the 
expression of NF-κB, but also totally abolished the 5-Fu-induced expression of NF-κB in both 5-Fu resistant cell 
lines (Fig. 2C). Similarly, the 5-Fu-induced NF-kB DNA binding activity was completely prevented upon aspirin 
treatment in both chemoresistant CRC cell lines (Fig. 2D).
One of the crucial steps to activate the NF-kB pathway was the phosphorylation by IKK-β and IKK-β and 
IKK-α; as a result, we investigated whether aspirin inhibited the activation of the NF-kB pathway through sup-
pressing the expression of p-IKK-β and p-IKK-α. Our findings revealed that aspirin ectopically reduced the 
expression of p-IKK-β but not that of p-IKK-α (data not shown) in the chemoresistant CRC cells (Fig. 2E). 
Moreover, aspirin also suppressed the 5-Fu-induced expression of p-IKK-β.
In order to further confirm whether enhanced the cytotoxicity of 5-Fu in chemoresistant CRC cells on 
depended on the NF-kB pathway, BAY11-7082, a NF-κB inhibitor, was used to block NF-κB signaling. According 
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Figure 1. Aspirin overcomes the resistance to 5-Fu and enhances the sensitivity to 5-Fu in CRC cells. (A) The 
established 5-Fu resistant CRC cell lines SW620-FU and SW480-FU were treated with indicated concentrations 
of aspirin (ASA) or 5-Fu (FU), respectively, and the cell viability was measured at 72 h through MTT assay. (B) 
SW480 and SW620 were treated by 2.5 mM ASA, 20 μM FU, or both of the two drugs (A + F), respectively, 
and the cell viability was measured at 48 h and 72 h, separately, by MTT assay. (C) SW480-FU and SW620-FU 
were treated by 2.5 mM ASA, 150 μM FU, or both of the two drugs (A + F), respectively, and the cell viability 
was measured at 48 h and 72 h, separately, by MTT assay. (D) CRC cells were treated as described above, and 
apoptosis was measured at 72 h later by FACS analysis. The data are presented as means ± SD (**P < 0.01, 
*P < 0.05).
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to our results, BAY11-7082, which was almost as strong as aspirin, significantly enhanced the sensitivity of 
SW620-FU cells to 5-FU, with drastically increased growth-inhibitory effects after treatment. However, the triple 
treatment with 5-Fu plus aspirin and BAY11-7082 did not show stronger growth-inhibitory effects than that 
in the combined treatment with 5-Fu plus aspirin (Fig. 2F, Supplementary Fig. 2A). Similarly, aspirin did not 
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Figure 2. Aspirin enhances the anti-tumor effect of 5-FU by inhibiting the 5-Fu-induced abnormal NF-κB 
abnormal in resistant CRC cells. (A) Nuclear protein was extracted and the basic expression levels of p65 in 
SW620, SW480, SW620-FU and SW480-FU were determined by Western blotting analysis. (B) NF-κB was 
detected by DNA binding in SW620, SW480, SW620-FU, and SW480-FU through the electrophoretic mobility 
shift assay (EMSA). (C) SW620-FU and SW480-FU cells were treated with 2.5 mM ASA, 150 μM (FU), or 
both of the two drugs (A + F), respectively, and the expression of nuclear p65 and p-p65 was measured at 
48 h through Western blotting analysis. β-Actin serves as a control. (D) The NF-κB activity in SW620-FU 
cells is analyzed by EMSA after 6 h of treatment as described above. Comp: a 10-fold excess of unlabeled 
oligonucleotide is added to the untreated cells for control DNA-binding reaction, followed by incubation with 
the biotin-labeled oligonucleotide probe for NF-κB. (E) The expression of IKK-β was measured at 48 h through 
Western blotting analysis as described above. (F) SW620-FU cells were treated with 150 μM FU alone, the 
double combination of 2.5 mM ASA plus 150 μM FU(A + F) or 10 μM Bay11-7082 (A + B), or triple agents 
combination (A + B + F), respectively, and the cellular viability was measured 72 h later with an MTT assay. (G) 
Western blotting was conducted 48 h after treatment with nonspecific control siRNA (NC) or p65 siRNA. (H) 
Cells were transfected with p65 siRNA for 24 h. Then, cells treated with 5-FU or aspirin or both agents together 
for another 72 h and the viability of cells were detected with MTT. (I)The indicated cells transfected with or 
without p65-siRNA for 24 h were treated with 5-FU or aspirin or both agents together for 24 hours, and the 
invasion cells were evaluated using the Transwell chambers coated with Matrigel.
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further improve the growth-inhibitory effect of 5-FU in both SW480-FU and SW620 cells with p65 knockdown 
(Fig. 2G,H, and Supplementary Fig. 2A). Next, we evaluated whether aspirin enhanced the invasion-inhibitory 
effect of 5-FU on CRC depends on the NF-kB pathway. Indeed, aspirin did not significantly improve the effect 
of 5-FU on the invasion of chemoresistant CRC cells with p65 knockdown by siRNA in these cells (Fig. 2I, and 
Supplementary Fig. 2B). These results demonstrated that aspirin enhanced growth- and invasion-inhibitory 
effects of 5-FU in CRC cells mainly through the NF-kB pathway.
The above results indicated that aspirin restored the sensitivity of chemoresistant CRC cells to 5-Fu, which was 
possibly achieved through inhibiting the 5-Fu-induced abnormal activation of NF-κB.
Aspirin and 5-Fu synergistically inhibited tumor growth in vivo. To assess the in vivo effects of aspi-
rin and 5-Fu alone or combination, both SW620 and 5-Fu-resistant SW620-FU cells were adopted in animal 
experiments. The final tumor volume was markedly lower in the combined treatment group than that in 5-Fu 
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Figure 3. Aspirin enhances the effects of 5-Fu on suppressing tumor growth in vivo. (A) SW620 cells are 
injected subcutaneously into the left flanks of nude mice. 28 mice were randomized into four groups and 
treated with water, ASA alone (200 mg/kg, daily), FU alone (20 mg/kg, twice/week), and the combination of 
FU and ASA with the same dose and frequency, respectively. The xenografts are resected on day 23 and the 
tumor volumes were measured and analyzed. (B) The final body weight of mice in each group was shown. 
(C) SW620-FU cells were injected subcutaneously into the left flanks of 40 nude mice (Day 0). 40 mice were 
randomized into 8 groups and treated by the method described in the Materials and Methods and euthanized 
on day 23, and representative tumor images of each group were displayed. The tumor growth curve after 
treatment was analyzed and shown. (D) The representative photographs of tumors. (E) The curve of body 
weight growth was shown. The diagram presents the single measurements and the means ± SD (**P < 0.01, 
*P < 0.05).
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alone or control group in the tumor-bearing SW620 mice (Fig. 3A), indicating the synergistic antitumor effect 
between aspirin and 5-Fu in vivo. In addition, the final body weight of mice was not markedly changed in each 
treatment group compared with that of control (Fig. 3B), suggesting that mice were well tolerant to the respective 
treatment.
Afterwards, the effects of each treatment on the growth of SW620-FU-derived tumors were also evaluated. 
The results demonstrated that aspirin treatment remarkably suppressed tumor growth in a dose-dependent man-
ner (Fig. 3C). 5-Fu treatment did not effectively suppress the growth of SW620-FU-derived tumors, even though 
its concentration was increased from 20 mg/kg to 25 mg/kg. However, the tumor volumes in all combined treat-
ment groups were dramatically smaller than that in 5-Fu alone or control group (Fig. 3C,D). Importantly, the 
weight growth curve suggested that the weight of nude mice in the 5-Fu treatment group was slower than that 
in the control group, even though the difference was not statistically significant, but the combined treatment of 
aspirin with 5-Fu did not aggravate such trend (Fig. 3E). Moreover, the liver and kidney function indexes revealed 
that the plasma levels of aspartate aminotransferase (AST) and blood urea nitrogen (BUN) were not markedly 
elevated in the combined treatment group relative to those in 5-Fu alone group (Supplementary Fig. 3), indicating 
that the mice were well tolerant to the combined treatment of 5-Fu (25 mg/kg, twice a week) and aspirin (200 mg/
kg, daily), without inducing additional liver and kidney toxicity.
To sum up, these data showed that aspirin had strong an antitumor effect even on 5-Fu resistant CRC cells, 
which enhanced the 5-Fu-induced toxicity to the resistant CRC cells without causing additional AEs in vivo.
Aspirin potentiated the effect of 5-Fu on the migration, invasion, and metastasis of 5-Fu-resistant 
CRC cells. Results of Transwell assays demonstrated that the number of migratory cells was obviously decreased 
after aspirin treatment, but not by 5-Fu treatment. Compared with the control group, the combined treatment group 
had suffered from the most significant decrease (P < 0.05) (Fig. 4A). To mimic its possible clinical setting and utility, 
an animal model of liver and spleen metastases had been established. In line with our in vitro results, it was found that 
aspirin treatment effectively reduced the metastatic nodes in spleen and liver compared with those in control or 5-Fu 
treatment group (Fig. 4B,C). Although 5-Fu treatment alone had a minimal effect on preventing the metastasis of 
chemoresistant CRC cells, aspirin treatment dramatically enhanced the efficacy of 5-Fu in a synergistic manner, and 
the greatest effect was observed in the combined treatment group. These results confirmed the antimetastatic activity 
of aspirin; besides, they suggested that aspirin dramatically enhanced the antimetastatic effect of 5-Fu on the chemore-
sistant CRC cells in vivo.
Aspirin abrogated NF-κB activation stimulated by 5-Fu in vivo. Afterwards, we investigated 
whether the inhibitory effect of aspirin on tumor growth in mice was associated with the suppression of NF-κB 
activation in vivo. Results of Western blotting indicated that aspirin alone evidently down-regulated the expres-
sion of p-p65 and p-IKK-β in tumor samples (Fig. 5A). More importantly, our animal studies revealed that aspirin 
abolished the 5-Fu-induced up-regulated expression of p-p65 and p-IKK-β Consistent with our Western blotting 
results, we discovered that aspirin strongly suppressed the DNA binding activity of NF-κB and attenuated the 
5-Fu-induced NF-κB activation in tumor samples (Fig. 5B). Furthermore, the expression levels of downstream 
genes regulated by NF-κB such as Survivin, Bcl-2, VEGF, and cyclin D1, were also determined, which were found 
to be involved in tumor survival and chemoresistance, angiogenesis, and proliferation, respectively. Western blot-
ting results suggested that aspirin notably down-regulated the expression levels of all these proteins, which were 
almost totally abolished by the combined treatment in SW620-FU tumor tissues. Moreover, Western blotting 
results also suggested that aspirin up-regulated the expression of pro-apoptotic factor cleaved caspase-3 while 
down-regulating that of the proliferative factor Ki67, and the strongest effect was observed in the combined treat-
ment group (Fig. 5C). The above results suggested that the underlying mechanism of the synergistic antitumor 
effect between aspirin and 5-Fu was possibly ascribed to the fact that aspirin abolished the 5-Fu-induced NF-κB 
activation.
Taken together, our findings indicated that aspirin enhanced the chemotherapy sensitivity of chemoresistant 
CRC tumors to 5-Fu probably by suppressing the NF-κB pathway.
Discussion
This study was the first to demonstrate that aspirin effectively re-sensitized the chemoresistant CRC cells to 5-Fu 
and potentiated the antitumor effects of 5-Fu on chemoresistant CRC cells without inducing additional AEs, 
which was achieved through suppressing the 5-Fu-induced activation of the NF-κB pathway.
Typically, chemotherapy resistance is a major cause of recurrence and metastasis after radical resection of 
CRC4,26. Although multi-drug combined therapy can partially improve the therapeutic effect, it can also lead to 
serious AEs4,27. Consequently, numerous CRC patients are forced to give up chemotherapy due to the toxicity of 
chemotherapeutics, which accounts for one of the leading causes of poor prognosis for CRC27. Our previous study 
suggested that aspirin evidently improved the efficacy of gemcitabine in pancreatic cancer17. In this study, our 
results showed that aspirin efficiently suppressed tumor metastasis and growth in the 5-Fu resistant CRC cells in 
a dose-dependent manner. Specifically, 100 mg/kg aspirin dramatically enhanced the therapeutic effect of 5-Fu, 
and such effect became more pronounced as the aspirin concentration increased. These results were consistent 
with those from previous studies showing that the administration of aspirin along with other compounds was 
more effective on suppressing CRC growth than either agent alone28,29; besides, aspirin might improve the clinical 
outcomes for CRC patients receiving capecitabine treatment29. Additionally, our study had demonstrated no 
cross-resistance between aspirin and 5-Fu.
5-FU at the dose of 20 mg/kg was given twice a week in this study based on a previous study30. Aspirin 
was administered at a dose of 100–200 mg/kg daily according to a previous report17,31 and the concentration 
of 2.5 mM aspirin used in our experiments was the pharmacologically relevant dose in clinical practice32. The 
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Figure 4. Combined application of aspirin and 5-Fu effectively inhibits the metastasis of chemoresistant CRC 
cells. (A) The invasion and migration capacities of SW620-FU and SW480-FU cells were determined using 
the Transwell chambers coated with or without Matrigel after 24 h of treatment with 2.5 mM ASA, 150 μM 
FU, or both of the two drugs (A + F). The average number of migratory cells was counted from five randomly 
selected fields., Representative photograph of the migrated cells was presented. The number of migratory cells 
in the control is set to 100%. (B) The spleen metastasis capacity of SW620-FU was assessed after treatment 
with ASA (200 mg/kg), FU (25 mg/kg), or both of the two drugs (A + F) in mice as described in the Materials 
and Methods. Left, representative photograph of the metastatic nodules in the spleen. (C) The liver metastasis 
capacity of SW620-FU was assessed after treatment described in the Materials and Methods. Left, representative 
photograph of the metastatic nodules in the liver. The number of metastatic nodules was counted and plotted. 
The data are presented as means ± SD (**P < 0.01, *P < 0.05).
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dose of 100 mg/kg aspirin daily in mice is equivalent to the dose 487 mg daily for humans weighing 60 kg17,20. 
Therefore, the dose of aspirin we used for mice from 100–300 mg/kg is almost equal to about 487 to 1461 mg daily 
for humans, which is a dose (300–1,500 mg daily) of aspirin used in previous clinical trials33. High-dose aspirin 
(approximately 4–10 g/d) is also used clinically for the treatment of type 2 diabetic and arthritis34,35. Thus, aspirin 
was applied here in doses comparable to their clinical use. In this study, aspirin even was given at a relatively high 
dose (200 mg/kg), the mice still demonstrated favorable tolerability, and no additional liver and kidney toxicity 
was observed in the combined treatment group compared with 5-Fu alone. Such results were consistent with the 
clinical evidence that aspirin was very well tolerated in human subjects, even it is given at a very high dose33. Our 
results had provided an experimental basis for the clinical application of aspirin in combination with 5-Fu-based 
chemotherapeutics for CRC patients, especially for those with poor chemotherapy tolerance.
Epidemiological evidence and animal studies have suggested that aspirin can inhibit the liver metastasis of 
CRC5,7,36, but such effect has not been validated in the chemoresistant CRC. Therefore, the antimetastatic effect of 
aspirin on the chemoresistant CRC was investigated in this study, and it was found that aspirin alone had obvious 
antimetastatic effect, while aspirin in combination with 5-Fu had demonstrated much stronger antimetastatic 
effect than that of either agent alone. This was consistent with a recent clinical trial, in which the combination of 
aspirin and capecitabine remarkably promoted the survival of patients with metastatic CRC that failed all previ-
ous chemotherapy due to chemoresistance37. These results had strongly supported the synergistic antimetastatic 
effect between aspirin and 5-Fu in chemoresistant CRC.
The constitutive activation of NF-κB plays a crucial role in the development and chemoresistance of CRC 
through driving the expression of pro-proliferative/anti-apoptotic genes38,39, which can be further activated by 
chemotherapeutics10,38,40. In this study, we found that the basic activity of NF-κB was evidently enhanced in CRC 
chemoresistant cells compared with that in parental cells, indicating that NF-κB activation might account for a 
potential mechanism that contributed to 5-Fu resistance. This was in line with the previous studies reporting 
that NF-κB was enhanced in the chemoresistant cancer cells, which was responsible for the resistance of tumor 
cells to treatment10,41,42. Notably, data from our study demonstrated that aspirin almost totally abolished the 5-Fu 
induced NF-κB activation in chemoresistant CRC cells both in vitro and in vivo. In addition, it potentiated the 
effect of 5-Fu on inhibiting the NF-κB-regulated proteins, including Survivin, Bcl-2, cyclin D1, and VEGF, which 
were involved in cell apoptosis, proliferation, chemoresistance, and metastases in CRC43–46. Such results were well 
consistent with those studies suggesting that NF-κB was activated by the conventional chemotherapeutics, which 
led to chemoresistance and inactivation of the NF-κB activity, and increased the sensitivity of tumor cells to 
chemotherapeutics20,40,47. Importantly, aspirin did not significantly enhance the growth- and invasion-inhibitory 
effects of 5-FU on chemoresistant CRC cells knockdown of p65 by siRNA in these cells. Based on these results, 
we hypothesized that the aberrant activation of NF-κB induced by 5-Fu was one of the major causes leading to 
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CRC chemoresistance and that aspirin enhanced the sensitivity of chemoresistant CRC cells to 5-Fu, which was 
possibly achieved through abolishing the 5-Fu-induced abnormal activation of NF-κB.
Our data had clearly suggested that aspirin monotherapy significantly suppressed tumor growth and metasta-
sis, and its combined application with 5-Fu potentiated the antitumor effects of 5-Fu in chemoresistant CRC cells 
through targeting NF-κB and its downstream targets, without increasing AEs. Noteworthily, in terms of toxicity 
and economic costs, aspirin may serve as a very promising antitumor agent to improve the efficacy of conven-
tional chemotherapy among CRC patients, especially for those with poor chemotherapeutic tolerance. However, 
further clinical studies are warranted to confirm our findings in CRC patients.
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